Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01608295 · ClinicalTrials.gov registry record · Phase 4
Vilazodone for Treatment of Geriatric Depression
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT01608295: Completed Phase 4 study, sponsored by University of California, Los Angeles.
NCT01608295 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 65 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01608295, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.
Primary Outcome
The HAMD measures the severity of depressive symptoms in participants with major depressive disorder (MDD). It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is the sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms.
Interventions
- DRUG Vilazodone; Viibryd
- DRUG Paroxetine; Paxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
What the finished NCT01608295 record still lists
NCT01608295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Vilazodone; Viibryd is the first listed.
NCT01608295 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01608295 about?
NCT01608295 is a clinical study titled "Vilazodone for Treatment of Geriatric Depression". The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.
What is the current status of trial NCT01608295?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2012-07. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01608295?
The interventions under investigation include: Vilazodone; Viibryd (DRUG), Paroxetine; Paxil (DRUG).
Who is sponsoring clinical trial NCT01608295?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01608295's enrollment target sits among peer trials
65 1091st of 2000 higher than 903 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia